Icon of the Instituts for Quality and Efficiency in Health Care

Report

Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

Status
Status: Commission completed
Project no.
A05-20A
Last updated

Report documents

  1. Final report version 1.1 (Erratum)

    Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

    published on
    Document type
    PDF document, 5 MB, DE, not accessible
    Download file : Final report version 1.1 (Erratum) (PDF document, 5 MB, DE, not accessible)

  2. Executive summary of the final report

    Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

    published on
    Document type
    PDF document, 251 kB, EN, not accessible
    Download file : Executive summary of the final report (PDF document, 251 kB, EN, not accessible)

  3. Final report

    Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

    published on
    Document type
    PDF document, 7 MB, DE, not accessible
    Download file : Final report (PDF document, 7 MB, DE, not accessible)

  4. Documentation and appraisal of comments on the preliminary report

    Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Documentation and appraisal of comments on the preliminary report (PDF document, 1 MB, DE, not accessible)

  5. Preliminary report

    Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

    published on
    Document type
    PDF document, 6 MB, DE, not accessible
    Download file : Preliminary report (PDF document, 6 MB, DE, not accessible)

  6. Report plan version 2.0

    Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

    published on
    Document type
    PDF document, 257 kB, DE, not accessible
    Download file : Report plan version 2.0 (PDF document, 257 kB, DE, not accessible)

  7. Documentation and appraisal of comments on the report plan version 1.0

    Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

    published on
    Document type
    PDF document, 9 MB, DE, not accessible
    Download file : Documentation and appraisal of comments on the report plan version 1.0 (PDF document, 9 MB, DE, not accessible)

  8. Amendment 1 to the report plan version 1.0

    Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

    published on
    Document type
    PDF document, 86 kB, DE, not accessible
    Download file : Amendment 1 to the report plan version 1.0 (PDF document, 86 kB, DE, not accessible)

  9. Report plan version 1.0

    Selective serotonin and norepinephrine re-uptake inhibitors (SNRI) in the treatment of depression

    published on
    Document type
    PDF document, 115 kB, DE, not accessible
    Download file : Report plan version 1.0 (PDF document, 115 kB, DE, not accessible)

Press releases

Antidepressants: benefit of SNRI is proven

Venlafaxine and duloxetine alleviate symptoms better than sham drug
Press release

Additional information

IQWiG health information

There are various treatment options for depression. They include psychological treatments, medication and general measures such as relaxation techniques or the use of sports and exercise.

How is depression treated?

Project details

Project no.
A05-20A
Commission
Commission awarded on 22.02.2005 by the Federal Joint Committee (GBA).
Report type
Report
Status
Commission completed
Department/Division
Drug Assessment
Topic
Mental and emotional wellbeing

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page